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REVIEW

Longitudinal Cardiovascular Outcomes of Sleep Disordered Breathing in
Children: A Meta-Analysis and Systematic Review
Zarmina Ehsan, MD1; Stacey L. Ishman, MD2,5; Thomas R. Kimball, MD3; Nanhua Zhang, PhD4; Yuanshu Zou, PhD4; Raouf S. Amin, MD5
Division of Pulmonary and Sleep Medicine, Children’s Mercy Hospital, Kansas City, MO; 2Division of Pediatric Otolaryngology–Head and Neck Surgery, Cincinnati Children’s
Hospital Medical Center, Cincinnati, OH; 3Division of Cardiology, Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 4Department of Biostatistics
& Epidemiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 5Division of Pulmonary and Sleep Medicine, Cincinnati Children’s Hospital Medical Center,
Cincinnati, OH
1

Objectives: The presence of sleep disordered breathing (SDB) is known to impact long-term cardiovascular morbidity in adults; however, the long-term effects
in children are poorly understood. We aimed to systematically review and synthesize studies published to date on the long-term effects of SDB in children.
Study Design: Meta-analysis and systematic review using PubMed, CINAHL, Embase, and Scopus (all indexed years).
Methods: We searched for English-language articles containing original human data from prospective studies, with ≥7 participants, in children ≤18 years
of age. Data regarding study design, demographics, clinical characteristics, outcomes, level of evidence, and risk of bias were obtained. Articles were independently reviewed by three investigators. Retrospective and cross-sectional studies were excluded.
Results: Of 1701 identified abstracts, 25 articles (combined n = 1418) were ultimately included. All studies reported longitudinal outcomes following treatment
of SDB, 21 studies exclusively reporting outcomes after adenotonsillectomy. Therefore, studies were combined to objectively assess the effect of SDB treatment
on cardiovascular outcomes. Although all cardiovascular parameters were within the normal range at baseline, at follow-up there was a significant decrease in
mean pulmonary artery pressure, right ventricular end diastolic diameter, heart rate, mitral Em/Am ratio, and C-reactive protein. There was no significant change
in interventricular septum thickness, left ventricular parameters (shortening fraction, systolic and end diastolic diameters, ejection fraction, posterior wall thickness, isovolumetric relaxation time), left atrial diameter, and aortic and pulmonary valve peak velocities.
Conclusions: Studies assessing the long-term cardiovascular effects of SDB in children are limited. The available literature indicates effects on autonomic
function, right, and left heart function following treatment for SDB. However, well-designed, large-scale, prospective cohort studies (using standardized outcomes) are needed to better understand the relationship of cardiovascular morbidity in the context of pediatric SDB.
Keywords: sleep disordered breathing, obstructive sleep apnea, cardiovascular, outcomes, children.
Statement of Significance
Studies prospectively assessing the long-term effects of OSA including the effect of treatment (either medical or surgical) on cardiovascular parameters in
children with obstructive sleep apnea are limited. Future prospective studies, utilizing polysomnography for diagnosis, are needed to better understand the
effects of OSA on cardiovascular outcomes in children.

INTRODUCTION
The estimated prevalence of pediatric obstructive sleep apnea
(OSA) is 1% to 5% with peak prevalence occurring between 2
and 8 years of age. This disease can result in significant morbidity to multiple organ systems.1 The effect of OSA on the
cardiovascular system has been well characterized in adult longitudinal cohort studies such as the Sleep Heart Health Study2;
however, pediatric studies are limited.3 In addition, many children are treated for OSA based upon the presence of sleep disordered breathing (SDB) symptoms, without formal diagnosis
of OSA. While single-center, cross-sectional studies assessing
the effect of SDB presence and treatment on cardiovascular
outcomes exist, longitudinal studies are few. Currently available systematic reviews are limited by the number of outcomes
reported or qualitative nature.4–7 There is one meta-analysis
of cohort studies on echocardiographic findings in pediatric
OSA.5 One limitation of this study is the sole inclusion of echocardiographic markers of cardiovascular disease, report of only
four outcomes, and meta-analysis comparing OSA to controls
without comparisons of outcomes before and after treatment
for OSA. Therefore, our aim was to systematically review the
literature regarding the long-term effects of SDB on cardiovascular outcomes in children and perform a meta-analysis of
previously reported cardiovascular outcomes in the context of
pediatric SDB.
SLEEP, Vol. 40, No. 3, 2017

MATERIALS AND METHODS
Study Selection
We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) recommendations
to perform this review (Figure 1). Studies were included if
they evaluated changes in cardiovascular parameters at 2 or
more time points, were prospective, contained an abstract,
involved only patients ≤18 years, were published in English
and included ≥7 subjects. We excluded review articles,
animal studies, and articles without original data. For the
meta-analysis section, we excluded studies with longitudinal
outcomes measured <1 month or >1 year from the reported
baseline. Studies documenting OSA or SDB were combined,
given the limited number of studies assessing cardiovascular outcomes using echocardiography in children with
polysomnogram confirmed OSA. Practice guidelines and
review articles were reviewed to identify additional studies.
This study was exempt from evaluation by the institutional
review board.
Types of Outcome Measures
Our primary outcomes of interest were cardiovascular abnormalities measured by echocardiography or another validated
test (electrocardiography, photoplethysmography, ultrasound)
1
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Figure 1—Flowchart for the identification of studies used in the systematic review and meta-analysis of the long-term cardiovascular outcomes of sleep disordered breathing (SDB) in children.

to identify relevant studies using combined key terms and
exploded Medical Subject Headings (MeSH; Table 1).
Three investigators (R.S.A., S.L.I., and Z.E.) independently
reviewed all identified titles, abstracts, and full-text articles.
Disagreements were discussed and resolved by consensus.
Outcomes were included in the meta-analysis if there were
2 or more studies, and the heterogeneity statistic (χ2) had a p
value > .05. For studies with incomplete results information,
we contacted authors via e-mail for additional data (2 of 12
responded).

and serum biomarkers of endothelial function. Outcomes were
organized in the following categories according to the function
that was measured: autonomic dysfunction, endothelial function, right heart morphology and function, and left heart morphology and function.
Data Sources and Study Selection
With the help of a medical librarian, we searched PubMed,
CINAHL, Embase, and Scopus on September 23, 2015,
SLEEP, Vol. 40, No. 3, 2017
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Table 1—Search methodology for systematic review and meta-analysis of the long-term cardiovascular outcomes of SDB in children.
Database

MeSH terms

PubMed

("Blood Vessels"[mesh]) OR "Hypotension"[mesh]) OR "pulse"[mesh]) OR "Coronary Artery Disease"[mesh]) OR
"Arrhythmias, Cardiac"[mesh]) OR "Stroke"[mesh]) OR "Hemodynamics"[mesh]) OR "Electrocardiography"[mesh]) OR
"Atrial Function"[mesh]) OR "Heart Failure"[mesh]) OR "Nitric Oxide"[mesh]) OR "Hypertension, Pulmonary"[mesh])
OR (((("Baroreflex"[mesh]) OR (("Pressoreceptors"[mesh]) OR Baroreceptor))))) OR "Chemoreceptor Cells"[mesh]) OR
"Natriuretic Peptides"[mesh]) OR "Cardiac Output"[Mesh]) OR "Heart Rate"[Mesh]) OR "Echocardiography"[Mesh]) OR
((("Ventricular Dysfunction"[Mesh] OR "Ventricular Dysfunction, Right"[Mesh] OR "Ventricular Dysfunction, Left"[Mesh]))))
OR "Ventricular Remodeling"[Mesh]) OR "Hypertension"[Mesh]) OR "Endothelium"[Mesh]) OR "Atherosclerosis"[Mesh]) OR
((("Autonomic Nervous System Diseases"[Mesh]) OR "Autonomic Nervous System"[Mesh]))) OR "Blood Pressure"[Mesh]) OR
"Cardiovascular System"[Mesh])) AND "Sleep Apnea Syndromes"[Mesh])) AND ((("Child"[Mesh]) OR "Adolescent"[Mesh]))))
AND english[Language])) AND ("Longitudinal Studies"[Mesh] OR "Prospective Studies"[Mesh] OR "Follow-Up Studies"[Mesh]
OR "Long-term"[All Fields] OR "long term"[All Fields] OR "Epidemiologic Study Characteristics as Topic"[Mesh] OR "Clinical
Trial" [Publication Type]) NOT "Cross-Sectional Studies"[mesh]

CINAHL

(MH "Blood Vessels+") OR (MH "Hypotension+") OR (MH "Hypertension+") OR (MH "Pulse+") OR (MH "Coronary
Arteriosclerosis") OR (MH "Arrhythmia+") OR (MH "Stroke+") OR (MH "Hemodynamics+") OR (MH "Electrocardiography+")
OR (MH "Heart Failure+") OR (MH "Nitric Oxide") OR (MH "Hypertension, Pulmonary+") OR (MH "Baroreflex") OR (MH
"Chemoreceptor Cells+") OR (MH "Natriuretic Peptides+") OR (MH "Cardiac Output+") OR (MH "Heart Rate+") OR (MH
"Echocardiography+") OR (MH "Ventricular Dysfunction+") OR (MH "Ventricular Dysfunction, Right") OR (MH "Ventricular
Dysfunction, Left+") OR (MH "Ventricular Remodeling") OR (MH "Endothelium") OR (MH "Atherosclerosis") OR (MH
"Autonomic Nervous System+") OR (MH "Autonomic Nervous System Diseases+") OR (MH "Blood Pressure+") OR (MH
"Cardiovascular System+")
((MH "Prospective Studies+") OR (MH "Nonexperimental Studies") OR (MH "Case Control Studies+") OR (MH "Correlational
Studies") OR (MH "Double-Blind Studies") OR (MH "Panel Studies+") OR (MH "Pseudolongitudinal Studies") OR (MH "TripleBlind Studies") OR (MH "Single-Blind Studies") OR (MH "Experimental Studies+")) NOT (MH "Cross Sectional Studies")

EMBASE

'blood vessel'/exp OR 'hypotension'/exp OR 'pulse rate'/exp OR 'coronary artery disease'/exp OR 'heart arrhythmia'/exp OR
'cerebrovascular accident'/exp OR 'hemodynamics'/exp OR 'electrocardiography'/exp OR 'heart atrium function'/exp OR 'heart
failure'/exp OR 'nitric oxide'/exp OR 'pulmonary hypertension'/exp OR 'pressoreceptor reflex'/exp OR 'chemoreceptor'/exp OR
'natriuretic factor'/exp OR 'heart output'/exp OR 'heart rate'/exp OR 'echocardiography'/exp OR 'heart ventricle function'/exp
OR 'heart left ventricle function'/exp OR 'heart right ventricle function'/exp OR 'heart ventricle remodeling'/exp OR 'hypertension'/exp OR 'endothelium'/exp OR 'atherosclerosis'/exp OR 'autonomic neuropathy'/exp OR 'autonomic nervous system'/exp
OR 'blood pressure'/exp OR 'cardiovascular system'/exp

Scopus

( ( TITLE-ABS-KEY ( sleep apnea ) AND TITLE-ABS-KEY ( child OR adolescent ) AND TITLE-ABS-KEY ( "Blood Vessels"
OR "Hypotension" OR "pulse" OR "Coronary Artery Disease" OR "Cardiac Arrhythmias " OR "Stroke" OR "Hemodynamics"
OR "Electrocardiography" OR "Atrial Function" OR "Heart Failure" OR "Nitric Oxide" OR "Pulmonary Hypertension " OR
"Baroreflex" OR "Pressoreceptors" OR baroreceptor OR "Chemoreceptor Cells" OR "Natriuretic Peptides" OR "Cardiac
Output" OR "Heart Rate" OR "Echocardiography" OR "Ventricular Dysfunction" OR "Ventricular Remodeling" OR
"Hypertension" OR "Endothelium" OR "Atherosclerosis" OR "Autonomic Nervous System Diseases" OR "Autonomic Nervous
System" OR "Blood Pressure" OR "Cardiovascular System" ) ) ) AND ( "long term" OR "long-term" OR longitudinal OR prospective OR "follow up" OR "follow-up" OR "clinical trial" OR "randomized controlled trial" ) AND ( LIMIT-TO ( LANGUAGE ,
"English" ) )

Data Extraction and Quality Assessment
For each study, we recorded the author, year of publication, study
design, inclusion criteria, intervention, length of follow-up, and
outcome. The level of evidence was determined according to
the Center for Evidence-Based Medicine guidelines.8 Triplicate
evaluation of the Newcastle-Ottawa Scale for assessment of
quality of nonrandomized studies in meta-analysis9 was used
(S-Table 2a). The Cochrane Collaboration tool for risk of bias10
was used to evaluate randomized controlled trials (S-Table 2b).

Test for overall effects were based on z-statistics and associated
p values.
A heterogeneity test was performed by using the χ2 and I2
statistics.12 We classified heterogeneity based on the following I2 threshold values: 0–40%: no significant heterogeneity;
30–60%: moderate heterogeneity; 50–90%: substantial heterogeneity; and 75–100%: considerable heterogeneity. For the χ2
statistic, a p value of < .05 was considered statistically significant heterogeneity. If there was a substantial heterogeneity, the
sources of heterogeneity were explored by removing studies
with low methodological quality. For studies with significant
heterogeneity, meta-analysis was not performed. All statistical
analyses were conducted using the “metafor” package in R version 3.2.3 (R Core Team, Vienna, Austria).13,14

Statistical Analysis and Effect Size Calculation
We used the DerSimonian and Laird11 random effects model to
calculate the summary post- and pre-intervention differences
for SDB subjects who underwent adenotonsillectomy (T&A).
Outcomes reported by OSA severity were combined; weighted
mean and pooled standardization were used for meta-analyses.
We calculated the mean differences (MD) and the 95% confidence intervals (CIs) and presented the results in forest plots.
SLEEP, Vol. 40, No. 3, 2017

RESULTS
Of the 1701 abstracts initially identified, 25 were included in the
final review (n = 1418). The mean Newcastle Ottawa score was
3
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8/9. All studies included adenotonsillectomy as an intervention, 21 exclusively. Of note, in four studies, a small proportion
of each cohort was treated with medical management (CPAP,
nasal steroids).15–17 Details of the included studies are reported
in Table 2. Key outcome measures that were consistent between
studies are depicted in S-Tables 3a-d. A description of the cardiovascular outcomes reported in this review are provided in the
Online Supplement. The mean ages ranged from 5 to 13 years
for the SDB and control groups (those who did not undergo
intervention). Sixteen studies used polysomnography to diagnose OSA, whereas nine diagnosed SDB clinically. The effect of
SDB treatment on cardiovascular outcomes are meta-analyzed
and reported susequently. We also performed a meta-analysis of
studies comparing SDB cases versus nondiseased controls. The
results are depicted in the Online Supplement (S-Figure 1–8).

studies reported estimated mean pulmonary artery pressure
(mPAP) using Mahan formula.19,33,36–39 After removing sources
of heterogeneity,33,36,38 there was a significant decrease in
mPAP (Figure 5; [MD −5.59;CI95%−7.19 to −3.99]). Two studies reported estimated pulmonary artery systolic pressure33,35;
although neither reported the proportion of children with pulmonary hypertension, both showed a significant improvement
at follow-up. Meta-analysis was not performed.
Three studies assessed interventricular septum thickness (IVS).35,40 There was no significant change at follow-up
(Figure 6; [MD −0.19;CI95% −0.69 to 0.31]). Four studies
assessed right ventricular diastolic diameter (RVDd).19,40–42
After removing sources of heterogeneity,41 there was a significant decrease in RVDd in the SDB group (Figure 7; [MD
−0.12;CI95% −0.20 to −0.03]. Two studies reported the right
ventricular myocardial performance index (RVMPi)33,42; both
showed a significant reduction (suggesting improvement) at
follow-up. Due to heterogeneity between studies, meta-analysis was not performed. The two studies assessing pulmonary
valve peak velocity showed no significant change at follow-up
(Figure 8; [MD 1.90; CI95%−0.31 to 4.12]). In reviewing unique
outcomes across studies, there were significant increases in
RV ejection time,42 time to peak velocity of pulmonary artery
flow(TPV),19 velocity–time integral of tricuspid flow(VTItv),1and velocity–time integral of pulmonary flow (VTIpa)7 and
a significant decrease in right ventricular isovolumetric relaxation time (IVRT)15 and tricuspid regurgitation (TR).43 There was
no significant change in tricuspid full diastolic filling time,34
tricuspid annular point systolic excursion,44 RV Isovolumetric
contraction time (IVCT),41 and tricuspid E/E’ (ratio of early tricuspid inflow to annular diastolic velocity).12

Autonomic Dysfunction
Two studies assessed blood pressure in SDB children.15,18 A significant decrease in asleep DBP at 6 months18 and asleep SBP
and DBP at 4 years after T&A15 were reported. Changes in
ambulatory BP parameters were not observed. Meta-analysis
was not performed.
Three studies assessed awake heart rate (HR).15,19,20 For the
two studies included in the meta-analysis, there was a significant decrease in HR at follow-up (Figure 2; [MD −2.97;CI95%
−5.18 to −0.77]). There was also a significant increase in RR
interval (n = 3 studies18,21,22; Figure 3; [MD 0.03;CI95%0.00,
0.06]). Additionally, there were significant improvements in
overnight baroreflex sensitivity,18 BP variability,15,18 asleep HR
and HR variability,16 and systolic and diastolic BP indices (in
those with resolved SDB)23 after treatment.
Endothelial Function
One study assessed endothelium-dependent, flow-mediated
dilation (FMD) using ultrasound of the brachial artery; it
reported a significant increase in FMD after AT in the surgical intervention group and no significant change after treatment
with nasal steroids in the nonsurgical group.24 One study used
a modified hyperemic test after cuff-induced occlusion of the
brachial artery, reporting a significant improvement in response
after treatment with AT25. After AT, there was a significant
decrease in endothelin-126, soluble CD40 ligand,25 NT-proBNP27
and morning brain natriuretic peptide level,28 an increase in circulating adropin concentration (in OSA children with endothelial dysfunction)29 and no significant change in cICAM-130.
Four studies assessed change in C-reactive protein.27,30–32 After
removing sources of heterogeneity,30 there was significant
decrease in C-reactive protein at follow-up (Figure 19; [MD
−0.41;CI95% −0.48 to −0.35]).

Left Heart Morphology and Function
Three studies assessed LV diastolic function (mitral E/A
ratio).17,34,35 After removing sources of heterogeneity,35 there was
no significant change in mitral E/A ratio at follow-up (Figure 9;
[MD 0.09; CI95% −0.22 to 0.40]. The two studies reporting
mitral Em/Am ratio showed a significant increase (Figure 10;
[MD 0.73;CI95%0.63 to 0.84]).33,35 Five studies assessed left
ventricle shortening fraction (FS).19,34,35,40,42 There was no significant change in FS (Figure 11; [MD −1.05, CI95%−2.25 to
0.16]). The four studies reporting left ventricular end-systolic
and end-diastolic diameter (LVSd and LVDd) showed no significant change in either LVSd(Figure 12; [MD 0.01; CI95%−0.08
to 0.09])34,35,40,42 or LVDd(Figure 13; [MD −0.06;CI95%−0.15 to
0.04])34,35,41,42 with treatment. Two studies reported left ventricle myocardial performance index(LVMPi)41,42; both reported a
significant decrease in LVMPi at follow-up. Meta-analysis was
not performed.
Three studies assessing left atrial diameter (LA) showed
no significant change (Figure 14; [MD 0.03;CI95%−0.06
to 0.12]).34,40,42 Analysis of two studies showed no significant change in either LV ejection fraction (Figure 15; [MD
−0.26;CI95%−3.02 to 2.50]) or aortic valve peak velocity
(Figure 16; [MD 1.70,CI95%−1.66 to 5.06]).34,35 The two studies assessing left ventricle posterior wall thickness (LVpw) also
showed no significant change (Figure 17; [MD −0.21,CI95%
−0.56 to 0.14]).35,40 Three studies reported left ventricular

Right Heart Morphology and Function
Three studies assessed change in tricuspid E/A ratio (peak early
filling to filling during atrial contraction).19,33–35 After removing
sources of heterogeneity,19,33 there was no significant change
in tricuspid E/A ratio at follow-up (Figure 4; [MD −0.02;CI95%
−0.08 to 0.04]. Two studies reported a significant increase in
tricuspid Em/Am ratio (early to late diastolic myocardial velocity). Meta-analysis was not performed (p = .0006).33,35 Six
SLEEP, Vol. 40, No. 3, 2017
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Table 2—Summary of included studies in the systematic review and meta-analysis summarizing the cardiovascular outcomes following treatment of SDB
in children.
Author

Abd ElMoneim et al.

Year

Design/
evidence
level

2009 Prospective
cohort (II)

No.

30 cases

Age, years

5
(2.5, 12)

Inclusion

SDB
with AH

PSG

Intervention

No

A

Interval
pre/post

Outcome

36 (30-52)
days

Tricuspid
E/A ratio

Results
SDB vs.
controls

SDB at
follow-up

No control
group

↑

FS

≈

RVDd

↓

Awake
HR

≈

mPAP

↓

VTItv

↑

VTIpa

↑

TPV

↑

Amin
et al.

2005 Prospective
case control
(III)

9 cases/
9 controls

12.3 (3.9)

ATH with
OSA

Yes

ATa

12 months

Mitral
E/A ratio

SDB <
controls

↑

Apostolidou
et al.

2008 Prospective
case control
(III)

58 cases/
17 controls

6.4 (3.3)

ATH with
OSA

Yes

AT

5.8 ± 2.9
months

CRP

pre
AT≈ controls

≈

cICAM-1

pre
AT≈ controls

≈

Systolic
BP Index

pre
AT≈ controls

↑ in
unresolved/
controls ↓ in
resolved

Diastolic
BP index

pre
AT≈ controls

↑ in
unresolved/
controls ↓ in
resolved

RVDd

pre
AT> controls,
post≈
controls

↓

mPAPa

pre
AT> controls,
post≈
controls

↓

PASP

pre
AT> controls,
post≈
controls

↓

Tricuspid
E/A ratio

pre
AT < controls
(mod-severe
OSA),
post≈ controls

↑

LVMi
(gm/m2)

pre
AT>controls,
post≈
controls

↓

Attia
et al.

2010 Prospective
case control
(III)

SLEEP, Vol. 40, No. 3, 2017

42 cases/
45 controls

5 (3.14)

ATH with
OSA

Yes

5

AT

6.4 +0.56
months

Cardiovascular outcomes in pediatric OSA—Ehsan et al.

Table 2—Continued
Author

Year

Design/
evidence
level

No.

Age, years

Inclusion

PSG

Intervention

Interval
pre/post

Outcome

Results
SDB vs.
controls

SDB at
follow-up

Mitral
Em/Am
ratio

Pre
AT < controls,
post AT≈
controls

↑

Tricuspid
Em/Am
ratio

Pre
AT< controls,
post AT≈
controls

↑

LV
MPI

Pre
AT>controls,
post AT≈
controls

↓

RVMPI

Pre
AT>controls,
post AT≈
controls

↓

Baumert
et al.

2011 Prospective
case control
(III)

40 cases/
40 controls

7.5 (2.7)

ATH with
OSA

Yes

AT

6 mo (29.2 +
- 5.9 wks)

RR
intervalⱡ

Pre
AT≈controls,
post AT≈
controls

↑

Chan
et al.

2015 Prospective
case control
(III)

63 cases/
63 controls

10.3 (2.9)

ATH with
OSA

Yes

ATa

6 months

FMD of
brachial
artery

Pre
AT<controls,
post AT≈
controls

↑

Cincin
et al.

2014 Prospective
case control
(III)

30 cases/
30 controls

7.86 (3.83)

SDB with
ATH

No

AT

6 months

mPAP

pre
AT> controls

↓

LVDd

pre
AT≈ controls

≈

LVSd

pre
AT≈ controls

≈

FS

pre
AT≈ controls

≈

RVDd

pre
AT≈ controls

≈

LVMPI

pre
AT≈ controls

↓

RVMPI

pre
AT> controls

↓

LA

pre
AT≈ controls

≈

Mitral E/E'

pre
AT≈ controls

≈

LV IVCT

pre
AT≈ controls

≈

LV IVRT

pre
AT≈ controls

↓

LV ET

pre
AT≈ controls

↓

SLEEP, Vol. 40, No. 3, 2017
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Table 2—Continued
Author

Crisalli
et al.

Year

Design/
evidence
level

2012 Prospective
case control
(III)

No.

133 cases/
61 controls

Age, years

9.4 (2.2)

Inclusion

ATH with
OSA

PSG

Yes

Intervention

AT

Interval
pre/post

6 weeks and
6 months

Outcome

Results
SDB vs.
controls

SDB at
follow-up

Tricuspid
E/E'

pre
AT≈ controls

≈

RV IVCT

pre
AT≈ controls

≈

RV IVRT

pre
AT≈ controls

↓

RV ET

pre
AT< controls

↑

TAPSE

pre
AT≈ controls

≈

Awake
SBP

pre
AT ≈ controls

≈

Awake
DBP

pre
AT≈ controls

≈

Asleep
SBP

↓(severe OSA)

Asleep
DBP

↓(severe OSA)

Asleep
RR

pre
AT ≈ controls

≈

BRS

severe
OSA < controls

↑

BPV
Goldbart
et al.

2010 Prospective
case control
(III)

90 cases

19 (7)
months

ATH with
OSA

Yes

AT

3 months

↓

CRP

Not
reported

↓

NTproBNP

pre
AT> controls

↓

TR
Gorur
et al.

2001 Prospective
case control
(III)

SLEEP, Vol. 40, No. 3, 2017

33 cases/
33 controls

6.3 (2.1)

SDB with
ATH

No

7

AT

6 months

↓

RVDd

pre
AT> controls,
post AT ≈
controls

LVSd

pre
AT≈ controls,
post AT ≈
controls

LVDd

pre
AT> controls,
post AT ≈
controls

IVS

pre
AT> controls,
post AT ≈
controls

FS

pre
AT≈ controls,
post AT ≈
controls

Cardiovascular outcomes in pediatric OSA—Ehsan et al.

Table 2—Continued
Author

Year

Design/
evidence
level

No.

Age, years

Inclusion

PSG

Intervention

Interval
pre/post

Outcome

Results
SDB vs.
controls

LA

pre
AT≈ controls,
post AT ≈
controls

LV IVRT

pre
AT≈ controls,
post AT ≈
controls

DT

pre
AT> controls,
post AT ≈
controls

VE

pre
AT≈ controls,
post AT ≈
controls

LVPW

pre
AT≈ controls,
post AT ≈
controls

VA

pre
AT≈ controls,
post AT ≈
controls

SDB at
follow-up

Gozal et al.

2007 Prospective
case control
(III)

26 cases/
8 controls

6.9 (0.6)

OSA with
ATH

Yes

AT

4-6 months

Modified
hyperemic
test

pre
AT< controls,
post AT≈
controls

↑

Gozal et al.

2013 Prospective
case control
(III)

35 cases/
35 controls

7.2 (1.4)

OSA with
ATH

Yes

AT

Not reported

Adropin
level

OSA/EF+
<OSA/
EF-<control

↑ in EF+,≈ in
EF-

Kaditis et al.

2011 Prospective
cohort (II)

21 cases

7.1 (2.8)

ATH with
OSA

Yes

AT

4.2+-1.2
months

RR
interval

↑ (except
stage 1)

logBNP

↑

KheirandishGozal et al.

2006 Prospective
cohort (II)

20 cases

Martha et al.

2013 Case-Control
prospective
(III)

33 cases/
10 controls

Moghaddam
et al.

2011 Prospective
case control
(III)

Naiboglu et al.

Pac et al.

ATH with
OSA

Yes

AT

10-14 weeks

CRP

6.7

SDB with
ATH

No

AT

2-24 wks
post op

mPAP

↓ (PH), ≈
(Non PH)

55 cases/
55 controls

3 to 11

SDB with
ATH

No

AT

6 months

mPAP

↓ (PH group
only)

2008 Prospective
case control
(III)

39 cases/
20 controls

5.7 (1.9)

SDB with
ATH

No

AT

6 months

mPAP

pre
AT> control,
post AT≈
controls

↓

2005 Prospective
case control
(III)

28 cases/
35 controls

7.3 (2.9)

SDB with
ATH

No

AT

1 month

Mitral
E/A ratio

pre AT≈
control

≈

Tricuspid
E/A ratio

pre AT≈
control

≈
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No control
group
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Table 2—Continued
Author

Year

Design/
evidence
level

No.

Age, years

Inclusion

PSG

Intervention

Interval
pre/post

Outcome

Results
SDB vs.
controls

SDB at
follow-up

FS

pre AT≈
control

≈

IVS

pre AT≈
control

≈

LVSd

pre AT≈
control

≈

LVDd

pre AT≈
control

≈

LVPW(endsystolic)

pre AT≈
control

≈

LVPW(enddiastolic)

pre AT≈
control

≈

LA

pre AT≈
control

≈

EF

pre AT≈
control

≈

Mitral
FDT

pre AT≈
control

≈

Tricuspid
FDT

pre AT>
control

≈

Aov Vel

pre AT≈
control

≈

Pulv Vel

pre AT≈
control

≈

Quante et al.

2015 Prospective
RCT (III)

202 cases

7 (4)

ATH with
OSA

Yes

AT

7 months

Awake
HR

No control
group

↓

Talipinar et al.

2011 Prospective
cohort (II)

37 cases

6.8 (2.9)

ATH with
SDB

No

AT/A/T

3-4 months

Endothelin-1

No control
group

↓

Ugur et al.

2008 Prospective
case control
(III)

29 cases/
26 controls

6.7 (2.4)

ATH with
OSA

Yes

AT/T

6 months

≈

CRP
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Mitral Em/
Am ratio

pre
AT> control,
post AT≈
control

↑

Tricuspid
Em/Am ratio

pre
AT> control,
post AT≈
control

↑

FS

pre AT≈
control

≈

IVS

pre AT≈
control

≈

LVSd

pre AT≈
control

≈

LVDd

pre AT≈
control

≈

PASP

pre AT>
control

↓
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Table 2—Continued
Author

Vlahandonis
et al.

Year

Design/
evidence
level

2013 Prospective
case control
(III)

No.

40 cases/
20 controls

Age, years

12.9 (0.3)

Inclusion

SDB

PSG

Yes

Intervention

Interval
pre/post

Outcome

Results
SDB vs.
controls

SDB at
follow-up

LVPW

pre AT≈
control

≈

EF

pre AT≈
control

≈

LVMi (gm/m)

pre AT≈
control

≈

RVDd (cm/m)

pre
AT≈control

≈

LV IVRT

pre AT≈
control

≈

Mitral E/A ratio

pre AT≈
control

≈

Tricuspid E/A
ratio

pre AT≈
control

≈

Aortic valve peak pre AT≈
velocity
control

≈

Pulmonary valve pre AT≈
peak velocity
control

≈

Awake DBP

SDB>
controls

≈

T&A in 9
children

Awake SBP

SDB>
controls

≈

T in 1

Asleep DBP

SDB>
controls

↓

Nasal steroid
in 1

Asleep SBP

SDB>
controls

↓

Combination
in 1

HR

followup≈
controls

≈

AT/Ta

4 years

Vlahandonis
et al.

2014 Prospective
case control
(III)

40 cases/
20 controls

12.9 (0.3)

SDB

Yes

AT/T a

4 years

BRS

↑ (resolved
OSA group)

Vlahandonis
et al.

2014 Prospective
case control
(III)

40 cases/
20 controls

12.9 (0.3)

SDB

Yes

AT/T a

4 years

BPV

↓

HRV

↓

Yilmaz
et al.

2005 Prospective
case control
(III)

52 cases/
33 controls

7.7 (2.5)

SDB with
ATH

No

AT

5 months

mPAP

pre AT>
control

↓

↑ or ↓indicates significant increase or decrease respectively, ≈ no significant difference, ⱡdetailed data obtained from author.
Abbreviations: ATH, adenotonsillar hypertrophy; AT,adenotonsillectomy; Aov Vel, aortic valve peak velocity; BNP,brain natriuretic peptide; cICAM-1, circulating intercellular adhesion molecule-1; CRP, C reactive protein; DBP,Diastolic blood pressure; E/A ratio,early to atrial filling velocity ratio; EF, ejection fraction;
Em/Am ratio,ratio of peak early to late diastolic filling velocity; FMD, flow-mediated dilation of the brachial artery; FS,LV Shortening fraction; HR, heart rate;
IVS, interventricular septum thickness; LVDd,Left ventricular end diastolic diameter; LVSd, LV end systolic diameter; LA, left atrial diameter; LVMPi,LV myocardial performance index; LVpw, left ventricle posterior wall thickness; LVIVRT, LV Isovolumetric relaxation time; mPAP, mean pulmonary artery pressure;
NT-proBNP, N- terminal prohormone brain natriuretic peptide; PASP, Pulmonary artery systolic pressure; PulvVel, pulmonary valve valve peak velocity;
RVDd, Right ventricular end-diastolic diameter; RVMPi, RV myocardial performance index; SBP,Systolic blood pressure; SDB, sleep disordered breathing; T,
tonsillectomy.
a
Subjects received medical or surgical treatment.
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Figure 2—Meta-analysis of studies on awake heart rate data
comparing before (pre) versus after (post) intervention.

Figure 6—Meta-analysis of studies on interventricular septum
thickness (IVS) data comparing before (pre) versus after (post)
intervention.

Figure 3—Meta-analysis of studies on RR interval data comparing before (pre) versus after (post) intervention.

Figure 7—Meta-analysis of studies on right ventricular end diastolic diameter (RVDd) data comparing before (pre) versus after
(post) intervention.

Figure 4—Meta-analysis of studies on Tricuspid E/A ratio data
comparing before (pre) versus after (post) intervention.

Figure 8—Meta-analysis of studies on pulmonary valve peak
velocity comparing before (pre) versus after (post) intervention.

Figure 5—Meta-analysis of studies on mean pulmonary artery
pressure (mPAP) data comparing before (pre) versus after (post)
intervention.
SLEEP, Vol. 40, No. 3, 2017

Figure 9—Meta-analysis of studies on mitral E/A ratio data comparing before (pre) versus after (post) intervention.
11

Cardiovascular outcomes in pediatric OSA—Ehsan et al.

Figure 10—Meta-analysis of studies on mitral Em/Am ratio data
comparing before (pre) versus after (post) intervention.

Figure 14—Meta-analysis of studies on left atrial dimension (LA)
data comparing before (pre) versus after (post) intervention.

Figure 11—Meta-analysis of studies on shortening fraction (FS)
data comparing before (pre) versus after (post) intervention.

Figure 15—Meta-analysis of studies on left ventricle ejection
fraction (EF) data comparing before (pre) versus after (post)
intervention.

Figure 12—Meta-analysis of studies on left ventricle end systolic
diameter (LVSd) data comparing before (pre) versus after (post)
intervention.

Figure 16—Meta-analysis of studies on aortic valve peak velocity
(Aov) data comparing before (pre) versus after (post) intervention.

Figure 13—Meta-analysis of studies on left ventricle end diastolic
diameter (LVDd) data comparing before (pre) versus after (post)
intervention.

Figure 17—Meta-analysis of studies on left ventricle posterior wall
thickness (LVPW) data comparing before (pre) versus after (post)
intervention.
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that early signs of cardiovascular dysfunction may be present in
these children. There is concern that childhood disruptions in the
cardiovascular system may result in lifelong cardiovascular morbidity, although further work is necessary to better understand
this relationship.46 It is important that we review currently available evidence carefully, as subtle (albeit non-significant) effects
on cardiovascular parameters may be additive over time.
There is sufficient evidence to suggest that severe OSA in
adults significantly increases the risk of cardiovascular disease,
stroke, and all-cause mortality.47–49 Adults with SDB, regardless
of severity, have a 2–3 time greater risk of developing hypertension at 4-year follow-up compared to controls.50 While the cardiovascular morbidity of OSA in children has been summarized
previously,51,52 meta-analyses are limited by low level of evidence, as the majority of published studies are cross-sectional
or retrospective,4–7 and available reviews are primarily qualitative in nature.53

isovolumetric relaxation time (LV IVRT).35,40,42 After removing
the source of heterogeneity,42 there was no significant change
at follow-up (Figure 18; [MD 3.50,CI95%−2.16 to 9.16]). One
study showed a decrease in LV mass (indexed to BSA),41 while
another reported no significant change in LV mass(indexed to
height).35 One study reported a significant decrease in LV ET42.
Changes in mitral E/E’,15 deceleration time,40 LV peak filling
velocity,33 LA contraction velocity,11 and LV IVCT45 were not
observed with treatment in individual studies.
DISCUSSION
In this systematic review and meta-analysis, we evaluated the
longitudinal cardiovascular changes reported for children with
SDB/OSA. All included studies reported outcomes before
and after treatment (primarily with T&A). Differences in outcomes in SDB/OSA children compared to controls at baseline
were also ascertained and depicted in the supplement. Overall,
we found that a number of measures improved after treatment,
but the mean values both before and after treatment were typically within the normal range. After treatment (most commonly
with T&A), these children had significant decreases in mPAP,
RVDd, awake HR, RVDd, and C-reactive protein and significant
increases in RR interval and mitral Em/Am ratio. These outcome
parameters are markers for pulmonary hypertension (mPAP), LV
diastolic function (mitral E/A), RV dysfunction (RVDd), baroreflex function (RR interval and awake HR), and endothelial dysfunction (C-reactive protein). Although the synthesis of results
is not definitively convincing for significant cardiovascular
strain at baseline, the change following treatment may suggest

Autonomic Dysfunction
Obstructive events during sleep lead to increased sympathetic
nervous system activation, which in turn may contribute to
elevated BP. Pediatric cross-sectional studies show that primary snoring and SDB is associated with increased BP.44,45,54–57
Our results indicate that upon resolution of OSA, there was a
significant decrease in nocturnal BP at 6-month18 and 4-year
follow-up58. Additionally, when evaluating the baseline characteristics of children included in this review, we found that when
compared to controls, children with SDB had higher baseline
nocturnal SBP and shorter RR interval (S-Figures 1–2). Carotid
sinus and aortic arch stretch receptors modulate the baroreflex
which is a feedback loop that regulates BP. Children with OSA
have altered baroreceptor sensitivity (BRS) which improves with
resolution of OSA.15,18,59 Although retrospective studies indicate
HR variability is altered in children with SDB,60,61 prospective
research is limited.16 The decrease in heart rate, improvements
in overnight baroreflex sensitivity,18 BP variability15,18 and heart
rate variability,16 and systolic and diastolic blood pressure indices (in those with resolved SDB)23 at follow-up suggests an
improvement in sympathetic imbalance after treatment of SDB.
Endothelial Function
OSA has also been linked to impaired endothelial function—a
risk factor for atherosclerosis-related vascular disease.62,63
Moreover, treating OSA with CPAP has been shown to improve
endothelial function.64 The majority of currently available pediatric evidence is cross-sectional in nature.65–69 When assessing
endothelium-dependent FMD of the brachial artery, the gold
standard in assessing endothelial function,70 OSA children have
lower values compared to controls at baseline, with reversal of
these changes after AT24. Measuring endothelial function with a
modified hyperemic test after cuff-induced occlusion of the brachial artery yields similar results suggesting an improvement in
endothelial function after OSA treatment.25 Prospective studies reporting serum biomarkers reflective of endothelial function provide further support that associations in the context of
OSA exist and improvement occurs after treatment. C-reactive
protein (CRP) is a marker of inflammation and a potentially
useful biomarker of cardiovascular morbidity. Studies reporting

Figure 18—Meta-analysis of studies on left ventricle isovolumetric
relaxation time (LVIVRT) data comparing before (pre) versus after
(post) intervention.

Figure 19—Meta-analysis of studies on c-reactive protein (CRP)
data comparing before (pre) versus after (post) intervention.
SLEEP, Vol. 40, No. 3, 2017

13

Cardiovascular outcomes in pediatric OSA—Ehsan et al.

that when compared to controls, SDB children had higher baseline LVMPi and lower mitral E/A ratio (S-Figures 7–8).
In summary, although the majority of cardiovascular parameters in children with SDB are within the normal range at
baseline, treatment has significant impact on markers of cardiovascular strain such as mean pulmonary artery pressure,
right ventricular end diastolic diameter, HR, and mitral Em/
Am ratio. Since cardiovascular effects are additive over time,
these results suggest that earlier diagnosis of SDB (and subsequent treatment) may prevent long-term cardiac morbidity. We
did not find any significant changes in interventricular septum
thickness, left ventricular parameters (shortening fraction,
systolic and end diastolic diameters, ejection fraction, posterior wall thickness, isovolumetric relaxation time), left atrial
diameter, and aortic and pulmonary valve peak velocities.
Given the paucity of available data, it is difficult to conclude
what cardiovascular parameters are most sensitive and relevant for this patient population. Certainly, more robust studies involving larger sample sizes may be more revealing. For
example, in order to design a randomized controlled trial with
equal numbers assigned to the treated and control group, one
will need 72, 356, and 12 subjects in each group (total of 144,
712, and 24 subjects) to detect a significant postintervention
difference in mPAP, RVDd, and mitral Em/Am ratio, respectively, to achieve 80% power at significance level of 0.05. For
a pre–post design in which subjects serve as their own control,
samples of 38, 180, and 8 will achieve 80% power respectively
for detecting significant pre- and post-treatment difference in
mPAP, RVDd, and mitral Em/Am ratio at a significance level
of 0.05.

C-reactive protein as a marker of inflammation in the context of
metabolic consequences of OSA were not within the scope of
this review. A comprehensive review of biomarkers related to
OSA has been previously reported71 as well as a meta-analysis
on the effects of T&A on C-reactive protein.72
Right Heart Morphology and Function
Although the baseline values for mPAP and estimated pulmonary artery systolic pressure in the majority of studies were
within normal range (<25 mm Hg) and the magnitude of
changes after T&A were small, our results suggest that improvement may be seen shortly following intervention. Reductions in
RVDd after intervention may indicate a decrease in RV dilation and improvement in RV reserve—although the magnitude
of improvement reported was marginal. When compared to
controls at baseline, we found that IVS thickness was significantly higher in SDB children (suggesting a potential effect
on RV pressure overload), but no significant improvement was
seen at follow-up. Although tricuspid E/A ratio did not change
significantly at follow-up, it is difficult to determine whether
the significant improvement in Em/Am ratio (albeit from a normal baseline) across individual studies represents normative
changes over time or is suggestive of improvement in diastolic
dysfunction after T&A. However, changes in RV ejection time,
RV MPi, VTItv, VTIpa, TPV, RV ET, and RV IVRT observed in
individual studies all suggest improvement in right heart morphology and function at follow-up. When evaluating the baseline characteristics of children included in this review, we found
that when compared to controls, children with SDB had higher
baseline mPAP, RVDd and IVS thickness, and lower tricuspid
E/A ratio (S-Figures 3–6).

LIMITATIONS
Our study had several limitations. The literature regarding longitudinal changes in cardiovascular parameters is limited, and
there is significant heterogeneity in diagnostic modalities and
outcomes reported. Standards regarding reporting of echocardiogram parameters exist although have not been consistently
used for research in this context. Some notable examples of this
are the inconsistent use of z-scores and the different methods of
indexing left ventricular mass by body size across studies. This
hinders quantitative comparisons across studies. Moreover,
only sixteen studies reported diagnosis of OSA based on polysomnography (the gold standard), while clinical symptoms
and questionnaires were used to identify SDB in the remainder.
Of the 16 studies documenting OSA with polysomnography,
only 3 reported echocardiogram findings (1 study only reporting one outcome). Outcomes assessed across studies were not
sufficient enough to separately consider these studies for quantitative analysis. Also, details regarding the severity of OSA,
as well as improvement in polysomnogram parameters after
treatment, were not consistently reported. Additionally, several
demographic parameters such as gender, ethnicity, and obesity
may have contributed to heterogeneity of outcomes (and potential confounding of results) and were not able to be controlled
for in our analysis. Obesity is a known major risk factor for cardiovascular disease, and it is key that this be factored for when
performing research studies pertaining to cardiovascular risk of
SDB. In pediatrics, the variability in terminology and metrics

Left Heart Dynamics and Function
Cross-sectional studies suggest that SDB is associated with elevated BP in children and linked to higher left ventricular mass
and left ventricular diastolic dysfunction.17,22,73 The E/A ratio
is a measure of diastolic function. Although baseline values
for mitral E/A ratios were normal (>1), there was a significant
increase in Em/Am ratio with treatment without a significant
change in E/A ratio. Since assessment of Em/Am using Tissue
Doppler Imaging is a more sensitive marker of diastolic dysfunction compared to E/A ratio assessment using traditional
echocardiography, these findings suggest that more sensitive
tools may be needed to detect these subtle changes in children. Although cross-sectional data suggests LV hypertrophy
in children with SDB,74 the two studies reporting LV mass at
follow-up reported conflicting results. Ugur et al. reported no
significant change at follow-up, while Attia et al. reported a
significant decrease in LVMi (indexed to BSA) at follow-up.
Although cohorts from both studies were of similar age and
nonobese, indexing left ventricular mass to height may be more
sensitive in detecting LVH. LVMPi is a sensitive diagnostic and
prognostic indicator of both systolic and diastolic dysfunction;
both studies reporting it showed a decrease with treatment as
well as significant elevations at baseline when compared to controls. Changes in other markers of left sided dysfunction such
as LVDd, LV EF, LA, LVpw LV IVRT, LVSd and FS were not
observed. Among the studies reported in this review, we found
SLEEP, Vol. 40, No. 3, 2017
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used to define obesity (body mass index [BMI], BMI percentile,
and BMI z-score) further complicates comparison across studies. Six studies did not report BMI data34,38,39,75–77; three reported
absolute BMI values35,41,78; two reported BMI percentiles79,80;
six reported BMI z-scores20,28,30,43,58,81; two specifically reported
excluding children with BMI > 2941, 82; one reported excluding
those with BMI z-score > 2.9920; and one reported body surface
area instead of BMI data.83 Despite these limitations, our review
provides a comprehensive synthesis and evaluation of the available literature regarding longitudinal changes in cardiovascular
parameters in children with OSA, reporting the largest collection of cardiac outcomes meta-analyzed to date.
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Available from: http://www.cebm.net/index.aspx?o=5653.
9. Wells G SB, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P.
The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013 [cited February 15, 2016];
Available from: http://www.ohri.ca/programs/clinical_epidemiology/
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February 15, 2016]; Available from: http://bmg.cochrane.org/
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in blood pressure control in elementary school-aged children with
sleep-disordered breathing. Sleep Med. 2014; 15(1): 83–90.
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heart rate variability in elementary school-aged children with sleep-disordered breathing. Sleep Med. 2014; 15(1): 76–82.
17. Amin RS, Kimball TR, Kalra M, et al. Left ventricular function in
children with sleep-disordered breathing. Am J Cardiol. 2005; 95(6):
801–804.
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after adenotonsillectomy in children with obstructive sleep apnea during
wakefulness and sleep. Sleep. 2012; 35(10): 1335–1343.
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21. Baumert M, Kohler M, Kabir M, et al. Altered cardio-respiratory
response to spontaneous cortical arousals in children with upper airway
obstruction. Sleep Med. 2011; 12(3): 230–238.
22. Kaditis AG, Alexopoulos EI, Dalapascha M, et al. Cardiac systolic function in Greek children with obstructive sleep-disordered breathing. Sleep
Med. 2010; 11(4): 406–412.
23. Apostolidou MT, Alexopoulos EI, Damani E, et al. Absence of blood
pressure, metabolic, and inflammatory marker changes after adenotonsillectomy for sleep apnea in Greek children. Pediatr Pulmonol. 2008;
43(6): 550–560.
24. Chan KC, Au CT, Chook P, et al. Endothelial function in children
with OSA and the effects of adenotonsillectomy. Chest. 2015; 147(1):
132–139.
25. Gozal D, Kheirandish-Gozal L, Serpero LD, Sans Capdevila O, Dayyat
E. Obstructive sleep apnea and endothelial function in school-aged nonobese children: effect of adenotonsillectomy. Circulation. 2007; 116(20):
2307–2314.
26. Tatlipinar A, Cimen B, Duman D, Esen E, Köksal S, Gökçeer T. Effect
of adenotonsillectomy on endothelin-1 and C-reactive protein levels in
children with sleep-disordered breathing. Otolaryngol Head Neck Surg.
2011; 145(6): 1030–1035.
27. Goldbart AD, Levitas A, Greenberg-Dotan S, et al. B-type natriuretic
peptide and cardiovascular function in young children with obstructive
sleep apnea. Chest. 2010; 138(3): 528–535.
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Gourgoulianis K. Effects of adenotonsillectomy on R-R interval and
brain natriuretic peptide levels in children with sleep apnea: a preliminary report. Sleep Med. 2011; 12(7): 646–651.
29. Gozal D, Kheirandish-Gozal L, Bhattacharjee R, Molero-Ramirez H,
Tan HL, Bandla HP. Circulating adropin concentrations in pediatric

CONCLUSION
Although cross-sectional studies in children show that SDB
is associated with significant cardiovascular comorbidities,
well-designed and long-term prospective studies are limited.
The currently available literature indicates that SDB impacts
sympathetic activity, right, and left heart function. Moreover,
the treatment of SDB may result in a reduction in cardiovascular strain. Well-designed, large-scale, prospective cohort studies
(using standardized outcomes) are needed to better understand
the relationship of cardiovascular morbidity and SDB.
Gaps
1. There is limited information regarding the long-term impact
of OSA on cardiovascular morbidity in children, and this literature is fraught with heterogeneity.
2. Studies prospectively assessing the effect of treatment (either medical or surgical) on cardiovascular parameters in
children with obstructive sleep apnea are limited.
3. Information regarding appropriate outcome measures to assess cardiovascular morbidity associated with pediatric OSA
is necessary.
4. Prospective studies, utilizing polysomnography for diagnosis, are needed to better understand the effects of complete
vs. partial treatment of OSA on cardiovascular parameters in
children.
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